

Full name of the study	Market Shaping for long-acting generic PrEP market
Technical Focus Area	Market Shaping for long-acting generic PrEP market
Summary of the study	Global efforts to scale up new long-acting PrEP options such as the dapivirine vaginal ring (DVR) and long-acting cabotegravir (CAB-LA), are some of the tools being deployed to end AIDS by 2030. These efforts will remain fundamentally curtailed by limited supply and high costs, therefore, it is important to accelerate generic product development to establish healthy markets and enable equitable access to the holistic package of PrEP options. Beyond CAB-LA and DVR, there are also a number of additional new long-acting technologies in the product development pipeline. Currently, there are several access barriers that need to be addressed in order to establish long-acting PrEP healthy markets (i.e., markets that ensure quality, availability, supply security, and affordability, among other factors). The project coordinates the execution of supply-side interventions to accelerate long acting PrEP product generic development and scale up by reducing access barriers, facilitating accelerated access to quality-assured long-acting generics and building healthy markets in LMICs. This project will work to reduce these access barriers, facilitate accelerated access to quality-assured long-acting generics and build healthy markets for them in LMICs and globally. The project will also address complexities and considerations that need to be managed to support the development, manufacturing, regulatory filings, commercial terms, and roll out of generic long-acting products. The timeframe for this work is three years from January 2024.
Primary objectives	The Market Shaping project will develop supply side interventions for new PrEP options, that address availability and affordability by reducing access barriers for new PrEP options and building a healthy market for these new PrEP options globally. • Develop supply side intervention options and assess potential impact of available options • Design and validate supply side interventions • Negotiate, execute, and implement supply-side interventions • Explore opportunities and partnerships for the regional manufacturing of viable PrEP options
Investigators	PI: Prof Saiqa Mullick Co PI: Vusile Butler
Donor name	Unitaid

Project Summary:

Coordinates the execution of supply-side interventions to accelerate long acting PrEP product generic development and scale up by reducing access barriers, facilitating accelerated access to quality-assured long-acting generics and building healthy markets in LMICs. Also addresses complexities and considerations that need to be managed to support the development, manufacturing, regulatory filings, commercial terms, and roll out of generic long-acting products.